For Research Use Only. Not for human consumption. The following summarizes published preclinical literature for laboratory research purposes only.
What It Is
Delta Sleep-Inducing Peptide (DSIP) is a nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, molecular weight ~849 Da) first isolated in 1977 from the cerebral venous blood of rabbits subjected to hypnogenic electrical stimulation of the intralaminar thalamus. It belongs to the broader class of neuromodulatory oligopeptides studied for effects on electroencephalographic (EEG) activity, and it is one of only two “sleep peptides” ever purified to homogeneity and structurally characterized (Graf & Kastin, Neurosci Biobehav Rev, 1984). The peptide’s name derives from its originally observed capacity to enhance delta-wave EEG activity following intraventricular infusion in animal models.
Summary of Published Preclinical Research
The foundational characterization work by Schoenenberger and colleagues synthesized DSIP along with several structural analogues and administered them intraventricularly to rabbits (n=61, including controls), reporting a “highly specific” enhancement of delta and spindle EEG activity — a mean 35% increase in delta power in neocortex and limbic cortex relative to controls (Schoenenberger et al., Naunyn Schmiedebergs Arch Pharmacol, 1978).
Subsequent rodent research has focused heavily on DSIP’s stress-modulating properties rather than sleep alone. In August-line and Wistar rats bred for differing stress resistance, intraperitoneal DSIP (60–120 nmol/kg) increased hypothalamic substance P content and reduced classic stress markers such as adrenal hypertrophy and thymic involution following emotional stress exposure (Koplik et al., Neurosci Behav Physiol, 1992). A related study using immobilization-stress and hypokinetic-stress rat models found that DSIP administration normalized stress-induced disturbances in brain GABA, glutamate, aspartate, and homocarnosine levels (Karkishchenko et al., Ukr Biokhim Zh, 1991).
Mechanistic work examining the hypothalamic-pituitary-adrenal (HPA) axis found that DSIP (0.1 mg/kg, i.p.) partially blocked stress-induced elevation of plasma corticosterone in a 6-hour immobilization rat model, implicating the HPA axis in the peptide’s stress-protective profile (Sudakov et al., Biull Eksp Biol Med, 1990). At the cellular level, DSIP has been shown to enhance oxidative phosphorylation efficiency in isolated rat brain mitochondria and to counteract hypoxia-induced reductions in mitochondrial respiratory activity (Kirsanova et al., Peptides, 2003), as well as to partially restrict hypoxia-induced changes in monoamine oxidase-A activity and serotonin content in rat brain tissue (FEBS Lett, 1995).
More recent work using a DSIP-derived analogue (KND peptide) in C57Bl/6 mouse models of focal cerebral ischemia and Sprague-Dawley rat models of myocardial infarction found that native DSIP administered at the reperfusion stage reduced infarct-area-to-area-at-risk ratio (28.7% vs. 42.1% in saline controls, p=0.01), supporting continued interest in DSIP’s neuroprotective and cardioprotective research applications (Stavchansky et al., Biomedicines, 2021).
Proposed Mechanism of Action
The published literature converges on a multi-pathway model rather than a single receptor target. Proposed mechanisms include: modulation of delta-wave EEG generation via thalamocortical circuits, originally demonstrated through direct intraventricular infusion studies; HPA-axis regulation, with DSIP attenuating stress-induced corticosterone release; neurotransmitter and neuropeptide balance, including normalization of GABAergic tone and elevation of hypothalamic substance P under stress; and mitochondrial bioenergetics, with DSIP enhancing oxidative phosphorylation and buffering hypoxia-induced metabolic disruption in brain tissue (Kirsanova et al., 2003 and Graf & Kastin, 1984).
Research Use & Handling Note
DSIP is supplied as a lyophilized (freeze-dried) powder for laboratory research applications only. This product is not manufactured for, and must not be used for, human or veterinary administration, diagnostic use, or any clinical purpose.